Plain-English translation of NCT06478472 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This clinical trial is testing whether a combination of two medications — orelabrutinib and rituximab — can help treat marginal zone lymphoma, a type of blood cancer. Researchers want to see if this treatment works well and is safe for patients whose cancer has come back after other treatments or who are not candidates for certain other therapies. The trial will enroll 36 patients.
Many patients with marginal zone lymphoma run out of treatment options when their cancer returns or progresses, or when standard treatments like surgery or radiation cannot be used. This trial exists to find out whether this medication combination offers a new, effective option for these patients.
You likely qualify if…
You likely don't qualify if…
You would receive treatment with the two medications, likely given by infusion or by mouth at a clinic or hospital setting. The trial will monitor your cancer using imaging tests like CT or PET scans, and check your blood work regularly to make sure the treatment is working and to watch for side effects. The study will follow your progress to evaluate how well this treatment combination works for your type of lymphoma.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Sponsor
The First Affiliated Hospital of Xiamen University
Collaborators
The First Hospital of Jilin University, Fujian Cancer Hospital
Enrollment target
~36 participants
Started
June 2024
Primary completion
June 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Bing Xu, PhD
The First Aiffiliated hosptical of xiamen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.